Business · 18/11/2009Updated: 10/17/2026 · 1 min read

FDA to Hold Public Meeting on Risk Evaluation and Mitigation Strategies for Opioid Drugs

Summary

The FDA is hosting a public meeting with sponsors of certain opioid drug products to discuss the development of Risk Evaluation and Mitigation Strategies (REMS) aimed at balancing the benefits and risks of these medications.

Original source language: Federal Register — Food and Drug AdministrationOpen original release →

Add your company to Business Communicator

We monitor business sources and connect attention with companies, profiles and services available in Business Communicator.

Create a free company profile Explore businesses on Business Maps →

Create a free company profile →

Explore insights

Business insights →

Healthcare Business News Global Markets News Trade Regulation News Business Technology News Fintech for Business: Payments & Banking News Supply Chain News

Related business signals

Business · 9/16/2026

Medicare Program; Public Meeting for New Revisions to the Healthcare Common Procedure Coding System (HCPCS) Level II Coding

The Centers for Medicare and Medicaid Services (CMS) will hold its second biannual Healthcare Common Procedure Coding System (HCPCS) Level II public meeting of 2026 to discuss new revisions to the HCPCS Level II code set for non-drug and non-biological items and services.

Read summary →

Business · 9/16/2026

Microbiology Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Pathogen-Agnostic Sequencing

The Food and Drug Administration (FDA) announces a public advisory committee meeting of the Microbiology Devices Panel to discuss pathogen-agnostic sequencing for emergency preparedness and response efforts.

Read summary →

Business · 9/16/2026

Order Under Sections 362 and 365 of the Public Health Service Act Continuing the Suspension of the Right To Introduce Certain Persons From Countries Where a Quarantinable Communicable Disease Exists

The Centers for Disease Control and Prevention (CDC) issued an Order under Sections 362 and 365 of the Public Health Service Act, continuing the suspension of introducing certain persons from countries with a quarantinable communicable disease outbreak.

Read summary →

Business · 9/15/2026

FDA Establishes Public Docket for Rare Disease Clinical Investigations Statistical Considerations

The FDA is collecting feedback on statistical considerations for rare disease clinical investigations through a public docket, which is open until a certain date, and a Rare Disease Innovation, Science, and Exploration (RISE) Workshop on the topic.

Read summary →

Business · 9/15/2026

National Cancer Institute Announces Closed Meeting

The National Cancer Institute has issued a notice regarding a closed meeting, which is not open to the public.

Read summary →

Business · 9/14/2026

NIH Proposes Enhanced Biosafety Policy for Biohazard Research

The National Institutes of Health is seeking public input on a new, comprehensive biosafety policy aimed at strengthening oversight and keeping pace with evolving biohazard risks, with the goal of ensuring gold-standard science under gold-standard biosafety conditions.

Read summary →